Intranasal neurostimulation yields positive results for dry eye diseaseThe first portable, external neurostimulator to be approved in eye care stimulates endogenous tear production without physical irritation. The device can dramatically reduce symptoms and may enable patients to stop use of some or all tear substitutes or medications, noted John Sheppard, MD, MMSc.
Using neurostimulation to treat dry eye
Using neurostimulation to treat dry eyeNeurostimulation could be the “next big thing” in dry eye disease (DED). A new neurostimulation device called TrueTear (Allergan) is a patient-directed, non-pharmacologic option.
Novel neurostimulator device uses nasal cavities to stimulate tearsChronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.
6 challenges when changing from a group to private practiceA little over 18 months ago, I decided to follow my passion and take a leap of faith changing my career. I went from a bustling MD/OD group practice to a private group OD practice and launched the Dry Eye Center of Pennsylvania (PA).
December 2014 New Products: Company acquires U.S. rights to interstitial cystitis formulationOther products discussed in this article include a prosthesis for underactive bladder, a prostate cancer test, and an erectile dysfunction drug.
AUA IC/BPS guideline update highlights new dataThe AUA has updated its guideline on interstitial cystitis/bladder pain syndrome, with changes primarily focusing on aspects of treatment for a condition that affects three to eight million women and one to four million men in the United States.
Abnormal impedances common with neurostimulationIf sacral neuromodulation has failed for your patient, look beyond the problem of lead position. Abnormal impedances are common and are frequently associated with revision, say researchers from Cleveland Clinic.